Filtered By:
Management: Mergers and Aquisitions

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 119 results found since Jan 2013.

All bleeding stops — but does idarucizumab (Praxbind) make it stop faster?
3.5 out of 5 stars Persistent life-threatening hemorrhage after administration of idarucizumab. Alhashem HM et al. Am J Emerg Med 2016 June 30 [Epub ahead of print] Reference Dabigatran (Pradaxa) is a direct thrombin inhibitor approved for stroke and embolism prophylaxis in patients with non-valve-related atrial fibrillation. When it was first released in 2008, a major disincentive to widespread use was the lack of a reliable reversal agent to treat major bleeds, or to administer before necessary invasive procedures. In October 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind), a monoclonal ant...
Source: The Poison Review - July 27, 2016 Category: Toxicology Authors: Leon Gussow Tags: Medical anticoagulant hemorrhage idarucizumab pradaxa praxbind reversal agent Source Type: news

The Proof is in the Pudding: Does tDCS Actually Deliver DC Stimulation?
Transcranial direct current stimulation (tDCS) is an increasingly used investigational modality for a variety of disease conditions worldwide, including stroke [1]. It is relatively easy to use, low-cost, and has a reasonable safety profile with currents up to 2  mA. The effect of tDCS on membrane potentials has been demonstrated in vitro [2] as well as in vivo through simulation of tDCS-generated electric fields [3]. Real-time monitoring of applied voltage and injected current in tDCS application is offered as an inbuilt feature of many tDCS devices and can be achieved with a simple data acquisition setup.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - May 10, 2016 Category: Neurology Authors: Pratik Y. Chhatbar, James R. Sawers, Wuwei Feng Tags: Letter to the Editor Source Type: research

Balt International buys Blockade Medical
European medtech firm Balt International said today it acquired endovascular device developer Blockade Medical for an undisclosed amount. The acquisition is part of Balt’s ongoing strategy to bolster its neurovascular portfolio as well as efforts to develop a presence in the U.S., the company said. “This acquisition is a first strategic move towards transforming Balt into an integrated global neurovascular device company. Balt is recognized as a 1st mover in the market thanks to a world-class R&D team, which has proven its ability and rapidity to develop blockbuster products such as the Leo stent, the Sil...
Source: Mass Device - September 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Catheters Mergers & Acquisitions Neurological Vascular Balt International Blockade Medical Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 16, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. St. Jude Medical’s HeartMate 3 implantable pump beats HeartMate II in pivotal trial The next-generation HeartMate 3 implantable pump St. Jude Medical acquired when it paid $3 billion for Thoratec last year proved superior to ...
Source: Mass Device - November 16, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Stealthy NeuroVasc Technologies raises $1m
Stealthy NeuroVasc Technologies said yesterday that it raised a $1 million funding round, taking it’s total raise since last year to nearly $2.5 million. Laguna Hills, Calif.-based NeuroVasc is led by CEO Ev3 veteran Jianlu Ma, according to regulatory filings. According to the LinkedIn page of chairman Jeff Peters, the former Anulex Technologies CEO who’s also an Ev3 alum, NeuroVascular Technologies is developing an interventional neuroradiology technology to treat ischemic stroke. The $1 million round included 3 unnamed investors, according to 1 of the filings. NeuroVascular Technologies reported raising $1...
Source: Mass Device - December 30, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neurological Vascular Wall Street Beat NeuroVasc Technologies Source Type: news

Stryker gains on Q4 prelims
Stryker (NYSE:SYK) shares are up after the orthopedics and hospital equipment giant posted preliminary financial results for the 4th quarter that narrowly beat the consensus forecast on Wall Street. The Kalamazoo, Mich.-based company said it expects a total revenue of $3.2 billion for Q4, up 16.3% from the same time last year. Analysts were looking for sales of $3.15 billion. “I am pleased with our performance in both the 4th quarter and the full year 2016,” chairman & CEO Kevin Lobo said in prepared remarks. “Fourth-quarter organic growth of 6.7% versus a strong prior year is impressive, and was ba...
Source: Mass Device - January 11, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Robot-Assisted Surgery Vascular Wall Street Beat Concentric Medical Inc. Stryker Source Type: news

Endothelial cell disease: emerging knowledge from cerebral cavernous malformations
Purpose of review: Endothelial cells dysfunctions are crucial determinants of several human diseases. We review here the most recent reports on endothelial cell defects in cerebral cavernous malformations (CCMs), particularly focusing on adherens junctions. CCM is a vascular disease that affects specifically the venous microvessels of the central nervous system and which is caused by loss-of-function mutation in any one of the three CCM genes (CCM1, 2 or 3) in endothelial cells. The phenotypic result of these mutations are focal vascular malformations that are permeable and fragile causing neurological symptoms and occasio...
Source: Current Opinion in Hematology - April 5, 2017 Category: Hematology Tags: VASCULAR BIOLOGY: Edited by Edward F. Plow Source Type: research

MassDevice.com +5 | The top 5 medtech stories for June 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. MassDevice Q&A: Claret Medical’s Azin Parhizgar on trying to make TAVR safer Cerebral protection developer Claret Medical recently won FDA de novo clearance for its Sentinel device designed to trap blood clots and prevent...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Stereotyped episodes of aphasia and immobility: how cataplexy mimics stroke in an elderly patient
E.A.: acquisition of data, interpretation of data, drafting the manuscript, revision of the manuscript, final approval to the final version to be published.
Source: Sleep Medicine - June 19, 2017 Category: Sleep Medicine Authors: E. Antelmi, F. Pizza, S. Vandi, G. Plazzi Tags: Video-Clinical Corners Source Type: research

Philips picks up EEG dev Electrical Geodesics for $37m
Royal Philips (NYSE:PHG) said today it has agreed to acquire Electrical Geodesics for $36.7 million (GBP£ 29 million). Amsterdam-based Philips said that EGI’s portfolio of EEG hardware, software and acquisition sensors would work to complement its existing imaging tech and advanced informatics portfolio for neurological applications. In the sale, Philips is offering $133.50 (GBP £105.40) for each EGI share, constituting a 36% premium to its June 21 closing value, the company said. The transaction is subject to customary closing conditions and stockholder approval, with a slated completion date in the 3rd quarter ...
Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Mergers & Acquisitions royal-philips Source Type: news

Penumbra picks up Italian distributor Crossmed for $9m
Penumbra (NYSE:PEN) said today it paid $9.4 million (EU €8.2 million) for all outstanding shares of Italian Crossmed S.p.a., which operated as the company’s exclusive distributor in Italy, San Marino and the Vatican. Alameda, Calif.-based Penumbra said that with the acquisition, Crossmed is now a wholly-owned subsidiary of the company.  Penumbra added that there are no material relationships between it and any of the sellers other than those pertaining to the acquisition. In addition to the initial payment, Penumbra said that it will also pay additional milestone payments based on Crossmed’s net revenue, &#...
Source: Mass Device - July 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Mergers & Acquisitions Penumbra Inc. Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 25, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. How a single drop of blood can detect sepsis Sepsis can be identified by a single drop of blood, thanks to a lab-on-a-chip device from the University of Illinois. Researchers at the University of Illinois and the Carle Foundati...
Source: Mass Device - July 25, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 18, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Study: New infrared imaging technique could help detect heart attack, stroke risk A new near-infrared diagnostic technique could help improve early detection for patients at risk of heart attacks or strokes, according to a new ...
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Integra LifeSciences completes purchase of J & J ’ s Codman Neurosurgery
Integra LifeSciences (Nasdaq: IART) has completed its previously announced $1.045 billion purchase of Johnson & Johnson’s Codman Neurosurgery business, the companies announced today. “The addition of Codman Neurosurgery expands our global leadership position by creating one of the broadest medical device portfolios in the neurosurgery market,” Peter Arduini, Integra’s president and CEO, said in a news release. “Our planned investments in product innovation and global infrastructure will allow us to provide more healthcare solutions to surgeons and their patients worldwide,” Arduini said. Integra...
Source: Mass Device - October 2, 2017 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News News Well Wall Street Beat Codman Neuro Integra LifeSciences Corp. johnsonandjohnson Natus Medical Inc. Source Type: news

Endonovo Therapeutics finally buys Rio Grande Neuroscience assets for nearly $5m
Nearly a year-and-a-half after their planned $22 million merger fell through,Endonovo Therapeutics (OTC:ENDV) said last week that it acquired intellectual property and assets from Rio Grande Neurosciences for $4.5 million. Rio Grande in August 2016 backed out of deal with Endonovo after seeking to renegotiate its terms when Steven Gluckstern, chairman & CEO of Santa Fe-based Rio Grande, dissolved a binding letter of intent. Los Angeles-based Endonovo, which had raised $10 million to fund the $21.5 million buyout, was to have put up $1.5 million in cash, another $15 million in ENDV shares and $5 million worth ...
Source: Mass Device - December 27, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Wall Street Beat Source Type: news